Immuneering (IMRX) vs MacroGenics (MGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MacroGenics (MGNX) has outperformed Immuneering (IMRX) over the past year, gaining 113.7% versus a loss of 36.9%. Over five years, MGNX leads with a -81.1% price change compared with -85.0% for IMRX. Immuneering is the larger company by market cap ($254.9 million vs $238.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | MGNX |
|---|---|---|
| Share price | $3.94 | $3.74 |
| Market cap | $254.91M | $238.24M |
| 1-day change | +5.35% | +5.35% |
| YTD return | -40.12% | +132.30% |
| 1-year return | -36.86% | +113.71% |
| 5-year return | -84.96% | -81.05% |
| EPS (TTM) | $-0.98 | $-1.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.48 | $5.08 |
| 52-week low | $3.60 | $1.29 |
| Distance from 52-week high | -53.54% | -26.38% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +335.79% | +113.90% |
| Average volume | 708.12K | 622.92K |
| Shares outstanding | 64.70M | 63.70M |
| Employees | 57 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed IMRX by 150.6 percentage points over the past year.
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
IMRX vs MGNX FAQ
Which is bigger, Immuneering or MacroGenics?
Immuneering (IMRX) is larger, with a market capitalization of $254.91M compared with $238.24M for MacroGenics (MGNX).
Which stock has performed better over the past year, IMRX or MGNX?
MGNX returned +113.71% over the past 12 months, compared with -36.86% for IMRX (price return, excluding dividends). Past performance does not predict future results.
Are Immuneering and MacroGenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.